Alberto Benussi1, Nicholas J Ashton2,3,4,5, Thomas K Karikari2, Stefano Gazzina6, Enrico Premi7, Luisa Benussi8, Roberta Ghidoni8, Juan Lantero Rodriguez2, Andreja Emeršič2,9, Giuliano Binetti10, Silvia Fostinelli8, Marcello Giunta1, Roberto Gasparotti11, Henrik Zetterberg2,9,12,13, Kaj Blennow2,9, Barbara Borroni1. 1. Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy. 2. Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden. 3. Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Mölndal, Sweden. 4. King's College London, Institute of Psychiatry, Psychology & Neuroscience, Maurice Wohl Clinical Neuroscience Institute, London, UK. 5. NIHR Biomedical Research Centre for Mental Health & Biomedical Research Unit for Dementia at South London & Maudsley NHS Foundation, London, UK. 6. Neurophysiology Unit, ASST Spedali Civili, Brescia, Italy. 7. Stroke Unit, ASST Spedali Civili, Brescia, Italy. 8. Molecular Markers Laboratory, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy. 9. Department of Neurology, University Medical Centre Ljubljana, Slovenia. 10. MAC Memory Clinic and Molecular Markers Laboratory, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy. 11. Neuroradiology Unit, University of Brescia, Brescia, Italy. 12. UK Dementia Research Institute at UCL, London, UK. 13. Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK.
Abstract
BACKGROUND: It is still unknown if serum glial fibrillary acidic protein (GFAP) is a useful marker in frontotemporal lobar degeneration (FTLD). OBJECTIVE: To assess the diagnostic and prognostic value of serum GFAP in a large cohort of patients with FTLD. METHODS: In this retrospective study, performed on 406 participants, we measured serum GFAP concentration with an ultrasensitive Single molecule array (Simoa) method in patients with FTLD, Alzheimer's disease (AD), and in cognitively unimpaired elderly controls. We assessed the role of GFAP as marker of disease severity by analyzing the correlation with clinical variables, neurophysiological data, and cross-sectional brain imaging. Moreover, we evaluated the role of serum GFAP as a prognostic marker of disease survival. RESULTS: We observed significantly higher levels of serum GFAP in patients with FTLD syndromes, except progressive supranuclear palsy, compared with healthy controls, but not compared with AD patients. In FTLD, serum GFAP levels correlated with measures of cognitive dysfunction and disease severity, and were associated with indirect measures of GABAergic deficit. Serum GFAP concentration was not a significant predictor of survival. CONCLUSION: Serum GFAP is increased in FTLD, correlates with cognition and GABAergic deficits, and thus shows promise as a biomarker of disease severity in FTLD.
BACKGROUND: It is still unknown if serum glial fibrillary acidic protein (GFAP) is a useful marker in frontotemporal lobar degeneration (FTLD). OBJECTIVE: To assess the diagnostic and prognostic value of serum GFAP in a large cohort of patients with FTLD. METHODS: In this retrospective study, performed on 406 participants, we measured serum GFAP concentration with an ultrasensitive Single molecule array (Simoa) method in patients with FTLD, Alzheimer's disease (AD), and in cognitively unimpaired elderly controls. We assessed the role of GFAP as marker of disease severity by analyzing the correlation with clinical variables, neurophysiological data, and cross-sectional brain imaging. Moreover, we evaluated the role of serum GFAP as a prognostic marker of disease survival. RESULTS: We observed significantly higher levels of serum GFAP in patients with FTLD syndromes, except progressive supranuclear palsy, compared with healthy controls, but not compared with ADpatients. In FTLD, serum GFAP levels correlated with measures of cognitive dysfunction and disease severity, and were associated with indirect measures of GABAergic deficit. Serum GFAP concentration was not a significant predictor of survival. CONCLUSION: Serum GFAP is increased in FTLD, correlates with cognition and GABAergic deficits, and thus shows promise as a biomarker of disease severity in FTLD.
Entities:
Keywords:
Biomarker; frontotemporal dementia; glial fibrillary acidic protein; magnetic resonance imaging; serum; survival; transcranial magnetic stimulation
Authors: Melissa A Rosenkranz; Douglas C Dean; Barbara B Bendlin; Nizar N Jarjour; Stephane Esnault; Henrik Zetterberg; Amanda Heslegrave; Michael D Evans; Richard J Davidson; William W Busse Journal: J Allergy Clin Immunol Date: 2021-09-15 Impact factor: 10.793
Authors: N J Ashton; A Leuzy; T K Karikari; N Mattsson-Carlgren; A Dodich; M Boccardi; J Corre; A Drzezga; A Nordberg; R Ossenkoppele; H Zetterberg; K Blennow; G B Frisoni; V Garibotto; O Hansson Journal: Eur J Nucl Med Mol Imaging Date: 2021-03-06 Impact factor: 9.236
Authors: Eino Solje; Alberto Benussi; Emanuele Buratti; Anne M Remes; Annakaisa Haapasalo; Barbara Borroni Journal: Diagnostics (Basel) Date: 2021-04-27
Authors: Jared S Katzeff; Fiona Bright; Katherine Phan; Jillian J Kril; Lars M Ittner; Michael Kassiou; John R Hodges; Olivier Piguet; Matthew C Kiernan; Glenda M Halliday; Woojin Scott Kim Journal: Brain Date: 2022-06-03 Impact factor: 15.255
Authors: Ahmed Abdelhak; Matteo Foschi; Samir Abu-Rumeileh; John K Yue; Lucio D'Anna; Andre Huss; Patrick Oeckl; Albert C Ludolph; Jens Kuhle; Axel Petzold; Geoffrey T Manley; Ari J Green; Markus Otto; Hayrettin Tumani Journal: Nat Rev Neurol Date: 2022-02-03 Impact factor: 44.711
Authors: Nuole Zhu; Miguel Santos-Santos; Ignacio Illán-Gala; Victor Montal; Teresa Estellés; Isabel Barroeta; Miren Altuna; Javier Arranz; Laia Muñoz; Olivia Belbin; Isabel Sala; Maria Belén Sánchez-Saudinós; Andrea Subirana; Laura Videla; Jordi Pegueroles; Rafael Blesa; Jordi Clarimón; Maria Carmona-Iragui; Juan Fortea; Alberto Lleó; Daniel Alcolea Journal: Transl Neurodegener Date: 2021-12-10 Impact factor: 8.014
Authors: Nicholas J Ashton; Marc Suárez-Calvet; Thomas K Karikari; Juan Lantero-Rodriguez; Anniina Snellman; Mathias Sauer; Joel Simrén; Carolina Minguillon; Karine Fauria; Kaj Blennow; Henrik Zetterberg Journal: Alzheimers Dement (Amst) Date: 2021-06-02
Authors: David Reyes-Leiva; Oriol Dols-Icardo; Sonia Sirisi; Elena Cortés-Vicente; Janina Turon-Sans; Noemi de Luna; Rafael Blesa; Olivia Belbin; Victor Montal; Daniel Alcolea; Juan Fortea; Alberto Lleó; Ricard Rojas-García; Ignacio Illán-Gala Journal: Front Neurol Date: 2022-01-18 Impact factor: 4.003